<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128856</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2002-01</org_study_id>
    <nct_id>NCT00128856</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients</brief_title>
  <official_title>Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT
      neoadjuvant regimen in patients with stage III breast cancer, confirmed by true-cut or open
      biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 treatment cycles of chemotherapy (one cycle = 2 weeks) must be administered to each patient
      before breast surgery.

      The required number of patients has been calculated following Simon's method. 43 patients
      will be enrolled in two phases: first, 29 patients must be enrolled, and at least 2
      pathological complete responses obtained. Patients recruitment will continue until 43
      patients have been enrolled. Assumptions are that there is a 95% probability to obtain a rate
      of pathological complete responses of at least 10%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2003</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>up to 5 months from last patient included</time_frame>
    <description>To determine the pathological response after surgery, based on the proportion of remaining tumor and post-chemotherapy changes, evaluating separately the response in the breast and in the axila lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete + partial responses)</measure>
    <time_frame>up to 3 months from last patient included</time_frame>
    <description>It is evaluated by measuring the target lesions before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conservative surgery rate</measure>
    <time_frame>up to 5 months from last patient included</time_frame>
    <description>Conservative surgery rate versus other sugery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 6 months from last patient included</time_frame>
    <description>According to the criteria CTC version 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years since surgery of last patient included</time_frame>
    <description>Time from the start of treatment to the progression of the disease (if it happens)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue molecular markers and correlation with response</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation of changes in the tumor marker profile before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>XPD single nucleotide polymorphisms (SNPs) and correlation with treatment response</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation of changes in the tumor before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusión followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <other_name>doxorubicin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III breast cancer disease, with histological confirmation by true-cut or
             open-biopsy.

          -  Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality
             of life to be eligible.

          -  Patients cannot have received previous treatment with chemotherapy, hormone therapy,
             radiotherapy or immune therapy.

          -  Performance status of 0,1, 2 (ECOG).

          -  At least a 6 month life expectancy.

          -  Neutrophils &gt; 1500; platelets &gt; 100000; haemoglobin &gt; 10 mg/dL.

          -  Adequate renal and hepatic functions, with serum creatinine &lt; 1.2 mg/dl and total
             bilirubin &lt; 2 mg/dl.

          -  Adequate contraceptive methods during the study and up to 3 months after.

          -  Adequate cardiac function assessed by physical exam, electrocardiogram (EKG) and left
             ventricular ejection fraction (LVEF) &gt; 55%.

        Exclusion Criteria:

          -  Inflammatory carcinoma or stage I, II or IV breast cancer disease.

          -  Males.

          -  Active infection.

          -  Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma
             adequately treated. Other previous neoplasms are allowed if diagnosed and treated more
             than 5 years before study registration.

          -  Concomitant serious disease provoking organ failure (heart, renal, hepatic,
             respiratory).

          -  Pre-existing motor or sensorial neuropathy &gt; grade 1.

          -  Inability for treatment compliance.

          -  History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K.

          -  History of arrhythmias or congestive heart failure, even when controlled; or active
             cardiac blocking of second or third grade.

          -  History of myocardial infarction in the previous 6 months.

          -  Hypertension (HT) not controlled.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalrio de Jaén</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Unviesitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Click here for more information about this study: GEICAM 2002-01</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy.</keyword>
  <keyword>Stage III disease.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

